Scientech Research LLC Acquires Shares of 10,574 Doximity, Inc. (NASDAQ:DOCS)

Scientech Research LLC bought a new position in shares of Doximity, Inc. (NASDAQ:DOCS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,574 shares of the company’s stock, valued at approximately $296,000.

A number of other institutional investors have also recently modified their holdings of DOCS. LRI Investments LLC purchased a new position in Doximity during the first quarter worth approximately $27,000. Blue Trust Inc. lifted its position in shares of Doximity by 621.4% during the 2nd quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock valued at $37,000 after buying an additional 1,193 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Doximity in the 1st quarter valued at $46,000. First Horizon Advisors Inc. increased its holdings in Doximity by 80.0% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,710 shares of the company’s stock worth $48,000 after acquiring an additional 760 shares in the last quarter. Finally, Van ECK Associates Corp raised its position in Doximity by 19.7% during the second quarter. Van ECK Associates Corp now owns 2,590 shares of the company’s stock worth $72,000 after acquiring an additional 427 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on DOCS. Evercore ISI lifted their target price on shares of Doximity from $29.00 to $34.00 and gave the company an “in-line” rating in a research report on Friday, August 9th. Robert W. Baird raised their target price on Doximity from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Morgan Stanley lifted their price target on Doximity from $25.00 to $26.00 and gave the stock an “underweight” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. increased their price objective on Doximity from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Monday, August 19th. Finally, Bank of America lifted their target price on shares of Doximity from $29.00 to $32.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $32.42.

Doximity Price Performance

Shares of DOCS stock opened at $43.56 on Tuesday. The firm’s 50-day moving average is $35.11 and its two-hundred day moving average is $29.70. The company has a market capitalization of $8.08 billion, a PE ratio of 60.50, a price-to-earnings-growth ratio of 5.80 and a beta of 1.27. Doximity, Inc. has a 12 month low of $19.89 and a 12 month high of $43.99.

Doximity (NASDAQ:DOCS) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.06. Doximity had a return on equity of 19.26% and a net margin of 32.53%. The company had revenue of $126.68 million during the quarter, compared to analyst estimates of $119.88 million. Sell-side analysts forecast that Doximity, Inc. will post 0.8 EPS for the current year.

Insider Buying and Selling at Doximity

In other Doximity news, CFO Anna Bryson sold 30,000 shares of Doximity stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $35.00, for a total transaction of $1,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 309,627 shares in the company, valued at $10,836,945. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Anna Bryson sold 30,000 shares of Doximity stock in a transaction on Friday, August 9th. The stock was sold at an average price of $35.00, for a total value of $1,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 309,627 shares of the company’s stock, valued at $10,836,945. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Watkin Phoebe L. Yang sold 1,940 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $28.22, for a total value of $54,746.80. Following the transaction, the director now directly owns 12,269 shares in the company, valued at approximately $346,231.18. The disclosure for this sale can be found here. Insiders have sold 35,451 shares of company stock valued at $1,201,018 over the last 90 days. 39.40% of the stock is owned by insiders.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.